Omnicell, Inc. (NASDAQ:OMCL) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of Omnicell, Inc. (NASDAQ:OMCL) have received an average rating of “Hold” from the six research firms that are covering the stock, Marketbeat.com reports. Four investment analysts have rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $52.00.

OMCL has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. upped their target price on Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Bank of America restated a “neutral” rating and issued a $57.00 price target (up previously from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Wednesday, November 27th. Barclays boosted their target price on shares of Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 31st. Finally, Benchmark reaffirmed a “buy” rating and set a $48.00 price target on shares of Omnicell in a research report on Wednesday, October 9th.

Omnicell Stock Performance

Shares of NASDAQ OMCL opened at $46.00 on Wednesday. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -117.95, a PEG ratio of 34.89 and a beta of 0.77. Omnicell has a 1 year low of $25.12 and a 1 year high of $55.74. The stock’s 50-day simple moving average is $44.90 and its 200-day simple moving average is $38.58.

Institutional Investors Weigh In On Omnicell

A number of institutional investors have recently modified their holdings of OMCL. Pacer Advisors Inc. lifted its holdings in Omnicell by 32.6% in the second quarter. Pacer Advisors Inc. now owns 2,070,434 shares of the company’s stock worth $56,047,000 after acquiring an additional 508,789 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Omnicell by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,180,503 shares of the company’s stock worth $31,955,000 after purchasing an additional 3,570 shares during the last quarter. Victory Capital Management Inc. boosted its position in Omnicell by 11,982.3% during the 3rd quarter. Victory Capital Management Inc. now owns 1,148,426 shares of the company’s stock valued at $50,071,000 after purchasing an additional 1,138,921 shares during the period. ArrowMark Colorado Holdings LLC grew its stake in Omnicell by 27.1% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 1,140,873 shares of the company’s stock worth $49,742,000 after buying an additional 243,353 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Omnicell by 0.3% in the third quarter. Geode Capital Management LLC now owns 1,104,745 shares of the company’s stock worth $48,176,000 after buying an additional 2,877 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.